Notwithstanding impressive growth IBSA is still on the frontier of its future corporate potential.

IBSA Institut Biochimque SA is a privately owned, pharmaceutical company headquartered in Lugano, Switzerland.
Founded in 1945 by a group of Swiss biologists, IBSA started its activities at a national level but rapidly became a consolidated company worldwide.
The current management acquired the control in 1985 and implemented an intensive development program with the aim of enlarging the company assets and creating a competitive product portfolio to be extended to international markets:

• 1945: foundation
• 1985: acquisition by the present management
• 1987: patent of diclofenac epolamine granted and partnership with Laboratoires Genévrier (France)
• 1992: acquisition of IBSA Italy and first registration of Merional®
• 1993: first registration of Flector EP Tissugel®
• 1995: opening of the new Hungarian branch, IBSA Pharma KFT
• 1996: acquisition of AMSA, Italy
• 1998: opening of the new headquarters and patent for hormones granted
• 1999: opening of new laboratories in Manno, Switzerland and Quingdao Huashan Biochemical, China
• 2001: acquisition of Gelfipharma, Italy
• 2002: opening of a new plant in Lamone, Switzerland
• 2003: opening of a new Slovakian branch, IBSA Slovakia s.r.o.
• 2004: acquisition of Rizhao Lanshan, China
• 2005: partnership with Altergon, Italy
• 2006: opening of a new plant in Manno, Switzerland
• 2007: opening of the new Turkish branch in Istanbul, IBSA Ilaç.
• 2008: entering the US market with Flector Patch®
• 2009: acquisition of Bouty Healthcare, Italy, now renamed IBSA Bouty.
• 2010: unification between AMSA and Gelfipharma, both merged into IBSA Farmaceutici Italia.

Currently IBSA has a head count of 1800 employees and sells its products covering
7 main therapeutic areas in 4 continents and more than 70 countries.
Each year the company manufactures about 10 millions vials of hormones,
more than 200 millions soft gel capsules and about 60 millions packages of finished products.